4.6 Article

Structure-based design of new N-benzyl-piperidine derivatives as multitarget-directed AChE/BuChE inhibitors for Alzheimer's disease

期刊

JOURNAL OF CELLULAR BIOCHEMISTRY
卷 -, 期 -, 页码 -

出版社

WILEY
DOI: 10.1002/jcb.30483

关键词

acetylcholinesterase; butyrylcholinesterase; in silico toxicity; molecular dynamics; multitarget ligands; neurodegenerative disease

向作者/读者索取更多资源

The complexity of Alzheimer's disease necessitates the development of multitarget-directed drugs. In this study, the chemical structure of the acetylcholinesterase inhibitor drug donepezil was modified to design new N-benzyl-piperidine derivatives as potential multitarget-direct inhibitors. In silico and in vitro methods were used to study the designed analogues, and the results showed that derivative 4a was the most potent inhibitor of both AChE and BuChE. This study highlights the potential of 4a as a novel multitarget-directed inhibitor.
The pathogenic complexity of Alzheimer's disease (AD) demands the development of multitarget-directed agents aiming at improving actual pharmacotherapy. Based on the cholinergic hypothesis and considering the well -established role of butyrylcholinesterase (BuChE) in advanced stages of AD, the chemical structure of the acetylcholinesterase (AChE) inhibitor drug donepezil (1) was rationally modified for the design of new N-benzyl- piperidine derivatives (4a-d) as potential multitarget-direct AChE and BuChE inhibitors. The designed analogues were further studied through the integration of in silico and in vitro methods. ADMET predictions showed that 4a-d are anticipated to be orally bioavailable, able to cross the blood -brain barrier and be retained in the brain, and to have low toxicity. Computational docking and molecular dynamics indicated the formation of favorable complexes between 4a-d and both cholinesterases. Derivative 4a presented the lowest binding free energy estimation due to interaction with key residues from both target enzymes (-36.69 +/- 4.47 and -32.23 +/- 3.99 kcal/ mol with AChE and BuChE, respectively). The in vitro enzymatic assay demonstrated that 4a was the most potent inhibitor of AChE (IC50 2.08 +/- 0.16 mu M) and BuChE (IC50 7.41 +/- 0.44 mu M), corroborating the in silico results and highlighting 4a as a novel multitarget-directed AChE/BuChE inhibitor.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据